Cannabics Pharmaceuticals Aktie [WKN DE: A116WM / ISIN: US13764M1009]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Cannabics Pharmaceuticals

04.08.21		World-Renowned Melanoma Expert Joins Cannabics Pharmaceuticals' Board of Advisors (PR Newswire)
20.07.21		Cannabics Pharmaceuticals Appoints a Second Independent Board Member (PR Newswire)
07.07.21		Cannabics Pharmaceuticals Announces Appointment of New Independent Board Member (PR Newswire)
28.06.21		Cannabics Pharmaceuticals' Drug Candidate Exhibits 30% Tumor Volume Reduction in Mice (PR Newswire)
17.06.21		Cannabics Pharmaceuticals to launch Drug Development Programs for Prostate Cancer and Neurodegenerative & Mental Health Diseases (PR Newswire)
26.05.20		Cannabics Pharmaceuticals to Capitalize on Israel's Final Approval for the Export of Medical Cannabis (PR Newswire)
27.01.20		Cannabics Pharmaceuticals Study Shows Cannabinoids CBC and CBG Exhibit (PR Newswire)
28.08.18		Cannabics Pharmaceuticals Inc. Appoints Dr. Estery Giloz-Ran to Its Advisory Board (PR Newswire)
22.05.18		Cannabics Pharmaceuticals Hires Two New Scientists to Further Develop Cannabinoid Diagnostic Tests and Treatments for Cancer (PR Newswire)
28.11.17		Cannabics Pharmaceuticals Received a New Research License for Characterization of Anti-Tumor Activity of Cannabinoids (PR Newswire)
25.09.17		Cannabics Pharmaceuticals Files National Phase Applications for Its System and Method for High Throughput Screening of Cancer Cells (PR Newswire)
06.09.17		Cannabics Pharmaceuticals Files a Patent Application for Sensitivity Tests of Cannabinoids on Patient Derived Tumor Biopsies and CTCs (PR Newswire)
28.08.17		Cannabics Pharmaceuticals Received Positive Report from The Patent Cooperation Treaty Regarding Cannabinoid Personalized Screening of Cancer Cells (PR Newswire)
24.07.17		Cannabics Pharmaceuticals Establishes a Human-Cannabis-Cancer Genetics lab to Expand its Personalized Diagnostics (PR Newswire)
12.07.17		Cannabics Pharmaceuticals Executed a Final Collaboration Agreement with SIMFO GmbH (PR Newswire)
11.07.17		Cannabinoid Market Growth Expands With Rising Influence of Pharma and Biotech Science Advancements (PR Newswire)
11.07.17		Cannabinoid Market Growth Expands With Rising Influence of Pharma and Biotech Science Advancements (PR Newswire)
30.06.17		Cannabics Pharmaceuticals Receives Positive Results in Drug Sensitivity Tests on CTCs (PR Newswire)
20.06.17		Substantial Expansion in Cannabis Operations and Grow Facilities in North America Leading to Increased Production and Revenues (PR Newswire)
20.06.17		Substantial Expansion in Cannabis Operations and Grow Facilities in North America Leading to Increased Production and Revenues (PR Newswire)
02.06.17		Cannabics Pharmaceuticals Inc. Provides Shareholders Update June 2017 (PR Newswire)
02.06.17		Cannabics Pharmaceuticals Inc. Provides Shareholders Update June 2107 (PR Newswire)
10.05.17		Cannabics Pharmaceuticals Raises $3,000,000 in Capital Raise Transaction (PR Newswire)
03.05.17		Cannabics Pharmaceuticals Announces Scientific Collaboration With A Leading CTC European Lab (PR Newswire)
03.04.17		Cannabics Pharmaceuticals Inc. Receives the Final Report of Its Research on Antitumor Properties of Cannabinoids Held in Israel (PR Newswire)
03.04.17		Cannabics Pharmaceuticals Inc. Receives the Final Report of Its Research on Antitumor Properties of Cannabinoids Held in Israel (PR Newswire)
21.03.17		Medicinal Cannabis Applications Target the Development of Enhanced Therapies and Treatments for Various Health Disorders (PR Newswire)
21.03.17		Medicinal Cannabis Applications Target the Development of Enhanced Therapies and Treatments for Various Health Disorders (PR Newswire)
09.03.17		Cannabics Pharmaceuticals Inc. Appoints New Members to its Board of Advisors (PR Newswire)
23.02.17		Cannabics Pharmaceuticals Inc. Provides Shareholders Update Regarding Increased Volume in its Shares (PR Newswire)
22.02.17		Cannabis Product Development for Cannabinoid CBD - THC Oil Formulas Leading to Higher Quality Medicinal Marijuana Therapies (PR Newswire)
22.02.17		Cannabis Product Development for Cannabinoid CBD - THC Oil Formulas Leading to Higher Quality Medicinal Marijuana Therapies (PR Newswire)
21.02.17		Pure Cannabis Concentrate & CBD Oil Product Demand Escalates in Legal Marijuana Market (PR Newswire)
21.02.17		Pure Cannabis Concentrate & CBD Oil Product Demand Escalates in Legal Marijuana Market (PR Newswire)
17.02.17		Americans' Favorable Outlook on the Cannabis Market (PR Newswire)
14.02.17		Breakthroughs in Cannabinoid (CBD) Therapies and Oral Products Prompting Optimism in Medicinal Marijuana Growth (PR Newswire)
14.02.17		Breakthroughs in Cannabinoid (CBD) Therapies and Oral Products Prompting Optimism in Medicinal Marijuana Growth (PR Newswire)
08.02.17		Israeli Innovation is at the Heart of a Growing Cannabis Ecosystem (PR Newswire)
08.02.17		Cannabis Asset Expansions and Acquisitions Quickly Becoming Catalyst For Exploding Marijuana Industry Growth (PR Newswire)
08.02.17		Cannabis Asset Expansions and Acquisitions Quickly Becoming Catalyst For Exploding Marijuana Industry Growth (PR Newswire)
07.02.17		Cannabics Pharmaceuticals Announces Initial Commercialization of Cannabinoids-based Personalized Diagnostics for Cancer Patients (PR Newswire)
01.02.17		FinancialBuzz.com: Macroeconomic Events May Benefit Small Caps (PR Newswire)
03.01.17		Cannabics Pharmaceuticals Announces a New Dosage of 5mg THC Cannabis Capsule Treating Cancer Patients Suffering from Cachexia and Anorexia Syndrome (PR Newswire)
05.12.16		Capital Infusion into Cannabis Industry Operations for Product Development and Acquisitions Fueling Major Sector Growth Possibilities (PR Newswire)
02.12.16		The Next Biggest Industry Could Potentially Be Cannabis (PR Newswire)
01.12.16		Cannabics Pharmaceuticals Announces Specific Ratios of Cannabinoids Led to Apoptosis in MDA-MB-231 Breast Cancer Cell Viability (PR Newswire)
29.11.16		Potential Booming of the "Green" Rush (PR Newswire)

Newssuche

Meistgelesene Nachrichten

Drohende Korrektur? Experte schlägt Alarm bei der NVIDIA-Aktie

Neuer Rekord nicht mehr weit: Bitcoin, Ethereum, Litecoin & Co.: Wie sich die Kryptokurse am Mittag entwickeln

Pierer Mobility-Aktie zweistellig im Plus: Pierer dementiert Mateschitz-Einstieg bei KTM

UN-Klimagipfel in Baku: Baerbock warnt vor 'Killerstürmen'

Angespannte Stimmung in Frankfurt: LUS-DAX gibt am Nachmittag nach

Nah an 100.000er Marke: Bitcoin, Dogecoin, Ethereum & Co. am Vormittag

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	26.11.2024 13:58
Kaufwert:	EUR
	Hinzufügen Speichern